Ohr Pharmaceuticals (NASDAQ:OHRP) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.

OHRP has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Ohr Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $0.75 price target for the company in a research report on Saturday, August 19th. Roth Capital began coverage on shares of Ohr Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright set a $10.00 price objective on shares of Ohr Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 16th.

Shares of Ohr Pharmaceuticals (NASDAQ OHRP) traded up $0.43 on Friday, hitting $1.28. 14,513,317 shares of the company’s stock were exchanged, compared to its average volume of 871,173. Ohr Pharmaceuticals has a 1-year low of $0.56 and a 1-year high of $2.70.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Garrison Bradford & Associates Inc. boosted its stake in shares of Ohr Pharmaceuticals by 482.4% in the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 412,000 shares during the period. Wedbush Securities Inc. purchased a new position in shares of Ohr Pharmaceuticals in the third quarter valued at approximately $311,000. Vanguard Group Inc. boosted its stake in shares of Ohr Pharmaceuticals by 0.7% in the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 5,481 shares during the period. Cannell Peter B & Co. Inc. purchased a new position in shares of Ohr Pharmaceuticals in the second quarter valued at approximately $187,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Ohr Pharmaceuticals by 242.3% in the first quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 162,600 shares during the period. 8.40% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Ohr Pharmaceuticals (OHRP) Lifted to “Sell” at ValuEngine” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/02/ohr-pharmaceuticals-ohrp-lifted-to-sell-at-valuengine.html.

Ohr Pharmaceuticals Company Profile

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.